Sana Hosni

4PUBLICATIONS
42CO-AUTHORS
Molecular targets
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (4)

|Jul 09, 2025
The Antibody-Drug Conjugate Sacituzumab Govitecan (IMMU-132) Represents a Potential Novel Therapeutic Strategy in Cholangiocarcinoma.

Racha Hosni, Niklas Klümper, Christine Sanders

|Jun 13, 2025
The Antibody-Drug Conjugate Sacituzumab Govitecan (IMMU-132) Represents a Potential Novel Therapeutic Strategy in Cholangiocarcinoma.

Racha Hosni, Niklas Klümper, Christine Sanders

|Jan 04, 2024
Adipocyte Precursor-Derived NRG1 Promotes Resistance to FGFR Inhibition in Urothelial Carcinoma.

Sana Hosni, Viola Kilian, Niklas Klümper

Pageof 1